PL2792674T3 - Związki imidazolidynodionu i ich zastosowania - Google Patents
Związki imidazolidynodionu i ich zastosowaniaInfo
- Publication number
- PL2792674T3 PL2792674T3 PL12858174.1T PL12858174T PL2792674T3 PL 2792674 T3 PL2792674 T3 PL 2792674T3 PL 12858174 T PL12858174 T PL 12858174T PL 2792674 T3 PL2792674 T3 PL 2792674T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazolidinedione compounds
- imidazolidinedione
- compounds
- Prior art date
Links
- 150000001468 imidazolidinediones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104188590A CN103159680A (zh) | 2011-12-14 | 2011-12-14 | 咪唑二酮类化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2792674T3 true PL2792674T3 (pl) | 2016-12-30 |
Family
ID=48583248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12858174.1T PL2792674T3 (pl) | 2011-12-14 | 2012-12-13 | Związki imidazolidynodionu i ich zastosowania |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9346764B2 (enExample) |
| EP (1) | EP2792674B1 (enExample) |
| JP (1) | JP5933746B2 (enExample) |
| CN (2) | CN103159680A (enExample) |
| AU (1) | AU2012350482B2 (enExample) |
| CA (1) | CA2859224C (enExample) |
| ES (1) | ES2587903T3 (enExample) |
| PL (1) | PL2792674T3 (enExample) |
| WO (1) | WO2013087004A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2940901T3 (es) * | 2013-05-29 | 2023-05-12 | Hinova Pharmaceuticals Inc | Compuesto de imidazol dicetona y uso del mismo |
| JP6346944B2 (ja) * | 2013-09-19 | 2018-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組み合わせ薬物療法 |
| WO2015054804A1 (zh) * | 2013-10-14 | 2015-04-23 | 杭州普晒医药科技有限公司 | 恩杂鲁胺的固态形式及其制备方法和用途 |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| US10131636B2 (en) * | 2014-10-01 | 2018-11-20 | Laurus Labs Limited | Process for the preparation of Enzalutamide |
| CN106432090B (zh) * | 2015-10-30 | 2019-08-20 | 成都海创药业有限公司 | 一种氘代咪唑酮化合物的晶型及其制备方法和用途 |
| CN107303278B (zh) * | 2016-04-25 | 2020-11-13 | 成都海创药业有限公司 | 一种hc-1119固体分散体及其制备方法 |
| CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
| JP6773915B2 (ja) | 2017-02-13 | 2020-10-21 | カング バイオファーマシューティカルズ リミテッド | 前立腺癌を治療する組み合わせ、薬物組成物および治療方法 |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| WO2019184952A1 (en) * | 2018-03-29 | 2019-10-03 | Hinova Pharmaceuticals Inc. | Deuterated imidazolidinedione compounds and their uses |
| CN110372598A (zh) * | 2018-04-13 | 2019-10-25 | 成都海创药业有限公司 | 一种合成氘代酰胺及氘代磺酰胺的新方法 |
| AU2019268481B2 (en) * | 2018-05-14 | 2025-04-03 | Hinova Pharmaceuticals Inc. | HC-1119 formulation, preparation method and use thereof |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| CN112442009B (zh) * | 2019-08-30 | 2023-10-03 | 润佳（苏州）医药科技有限公司 | 氘代化合物及其在治疗癌症方面的应用 |
| CN115380026B (zh) * | 2020-03-17 | 2023-11-07 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
| CN116322693A (zh) | 2020-08-13 | 2023-06-23 | 辉瑞公司 | 组合疗法 |
| CN114181155A (zh) * | 2021-12-21 | 2022-03-15 | 上海朝晖药业有限公司 | 碘-恩杂鲁胺及其制备方法及其应用 |
| CN115181043B (zh) * | 2022-07-27 | 2024-05-07 | 爱斯特（成都）生物制药股份有限公司 | 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| BRPI0709771B1 (pt) * | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| NZ596260A (en) * | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| CN101817787B (zh) * | 2009-02-26 | 2013-07-24 | 童友之 | 抗前列腺癌的雄性激素受体拮抗剂 |
| WO2011029392A1 (en) | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
-
2011
- 2011-12-14 CN CN2011104188590A patent/CN103159680A/zh active Pending
-
2012
- 2012-12-13 EP EP12858174.1A patent/EP2792674B1/en active Active
- 2012-12-13 WO PCT/CN2012/086573 patent/WO2013087004A1/zh not_active Ceased
- 2012-12-13 JP JP2014546301A patent/JP5933746B2/ja active Active
- 2012-12-13 US US14/364,147 patent/US9346764B2/en active Active
- 2012-12-13 CA CA2859224A patent/CA2859224C/en active Active
- 2012-12-13 CN CN201280052853.9A patent/CN104024228B/zh active Active
- 2012-12-13 AU AU2012350482A patent/AU2012350482B2/en active Active
- 2012-12-13 ES ES12858174.1T patent/ES2587903T3/es active Active
- 2012-12-13 PL PL12858174.1T patent/PL2792674T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103159680A (zh) | 2013-06-19 |
| US9346764B2 (en) | 2016-05-24 |
| CA2859224A1 (en) | 2013-06-20 |
| WO2013087004A1 (zh) | 2013-06-20 |
| AU2012350482A1 (en) | 2014-07-10 |
| CN104024228A (zh) | 2014-09-03 |
| US20140371284A1 (en) | 2014-12-18 |
| AU2012350482B2 (en) | 2017-02-16 |
| CN104024228B (zh) | 2015-07-08 |
| JP5933746B2 (ja) | 2016-06-15 |
| JP2015501820A (ja) | 2015-01-19 |
| HK1198166A1 (en) | 2015-03-13 |
| EP2792674A1 (en) | 2014-10-22 |
| CA2859224C (en) | 2019-03-19 |
| EP2792674A4 (en) | 2015-06-17 |
| EP2792674B1 (en) | 2016-05-25 |
| ES2587903T3 (es) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233051A0 (en) | Anti-phf-tau antibodies and uses thereof | |
| IL230511A0 (en) | 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors | |
| ZA201401434B (en) | Heterocyclic compounds and uses thereof | |
| IL230536A0 (en) | Heterocyclic compounds and their uses | |
| EP2678016A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| IL237309A0 (en) | Benzocyclooctyne compounds and uses thereof | |
| SI2614063T1 (sl) | Substituirani imidazopiridazini | |
| IL229844B (en) | Anti-psgl-1 antibodies and their use | |
| GB201111705D0 (en) | Compounds and their use | |
| SI2531518T1 (sl) | Oligopeptidne spojine in njihova uporaba | |
| GB201111630D0 (en) | Novel compounds and their use | |
| GB201106357D0 (en) | Composition and uses thereof | |
| GB201111775D0 (en) | Compounds and uses thereof | |
| GB201114448D0 (en) | Compounds and their use | |
| EP2782571A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| SG10201508549UA (en) | Modified tamavidin | |
| GB201121551D0 (en) | Compounds and uses thereof | |
| GB201121726D0 (en) | Compounds and uses thereof | |
| GB201214749D0 (en) | Compounds and their uses | |
| ME03310B (me) | 4-IMIDAZOPIRIDAZIN-1-jL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDl КАО INHIBITORI втк | |
| GB201101924D0 (en) | Compositions and uses | |
| GB201107454D0 (en) | Compositions and uses | |
| GB201104444D0 (en) | Compounds and their use | |
| GB201222342D0 (en) | Compounds and uses thereof | |
| GB201014319D0 (en) | Compounds and uses thereof |